Valuation: Mylan Inc

Market Cap 20.03B 17.89B 16.64B 15.14B 28.58B 1,939B 28.71B 200B 78.48B 988B 75.22B 73.58B 3,172B P/E 2026 *
75.7x
P/E 2027 * 46.6x
Enterprise Value 31.98B 28.56B 26.57B 24.17B 45.63B 3,095B 45.83B 320B 125B 1,578B 120B 117B 5,064B EV / Sales 2026 *
2.16x
EV / Sales 2027 * 2.04x
Free-Float
91.44%
Yield 2026 *
2.92%
Yield 2027 * 2.99%
Manager TitleAgeSince
Chief Executive Officer 63 2023-03-31
Director of Finance/CFO 59 2026-05-07
Chief Tech/Sci/R&D Officer - 2023-12-14
Director TitleAgeSince
Director/Board Member 78 2020-11-15
Director/Board Member 78 2020-11-15
Director/Board Member 62 2020-11-15
Change 5-day change 1-year change 3-year change Capi.($)
+0.46%+2.87%+37.45%+105.62% 1,043B
+1.43%+1.77%+36.36%+64.35% 618B
+1.44%+5.18%+19.83%+85.39% 481B
+2.62%+1.35%+67.15%+39.96% 351B
+1.45%+3.50%+21.87%+42.64% 338B
+1.17%+2.37%+11.71%+35.14% 269B
+0.89%+1.08%-7.28%+10.52% 244B
+2.20%+3.44%+41.12%+53.53% 220B
+2.60%+4.37%+29.40%+101.25% 182B
Average +1.71%+0.28%+28.62%+59.82% 416.3B
Weighted average by Cap. +1.41%+0.60%+31.45%+69.85%

Financials

2026 *2027 *
Net sales 14.79B 13.21B 12.29B 11.18B 21.1B 1,432B 21.2B 148B 57.95B 730B 55.54B 54.33B 2,342B 15.04B 13.43B 12.5B 11.37B 21.46B 1,456B 21.55B 150B 58.93B 742B 56.48B 55.24B 2,381B
Net income 142M 126M 118M 107M 202M 13.7B 203M 1.42B 554M 6.98B 531M 520M 22.41B 298M 267M 248M 226M 426M 28.88B 428M 2.98B 1.17B 14.72B 1.12B 1.1B 47.25B
Net Debt 11.95B 10.67B 9.93B 9.03B 17.05B 1,157B 17.13B 119B 46.82B 590B 44.88B 43.9B 1,892B 10.68B 9.54B 8.88B 8.07B 15.24B 1,034B 15.31B 107B 41.86B 527B 40.12B 39.24B 1,692B
Logo Mylan Inc
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Mylan Inc